Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T17:34:01.947Z.
Calculation as of: 2026-10-06T17:34:01.947Z.
Quote observation: 2026-10-06T17:30:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e4092e053989caac2e99517ddb979985c78622fc494c6088febce458b2dbbcab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
SAB Biotherapeutics, Inc.
Market Cap
$269.77M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.52M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$268.62M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$266.00M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$264.03M
Price/FCF Ratio
N/A
TTM Avg
4.69
3Y Avg
5.94
5Y Avg
441.51
Market Cap
$262.84M
Price/FCF Ratio
N/A
TTM Avg
61.29
3Y Avg
61.29
5Y Avg
61.29
Market Cap
$262.75M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | $269.77M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $269.17M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $268.62M | N/A | N/A | N/A | N/A |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.73M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.00M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | N/A | 4.69 | 5.94 | 441.51 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.84M | N/A | 61.29 | 61.29 | 61.29 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.75M | N/A | N/A | N/A | N/A |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.65M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
